| Document |
Document Title |
|
WO/2019/026994A1 |
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...
|
|
WO/2019/020654A1 |
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.
|
|
WO/2019/021836A1 |
The present invention relates to a vapor deposition raw material for manufacturing a platinum thin film or a platinum-compound thin film by a vapor deposition method. This vapor deposition raw material comprises an organoplatinum compoun...
|
|
WO/2019/022251A1 |
A (poly)amine compound represented by formula (0): (in formula (0), RX represents a C1-70 2nA-valent group or a single bond; R1A each independently represent an optionally substituted C1-30 alkyl group, an optionally substituted C6-30 ar...
|
|
WO/2019/020029A1 |
Disclosed are a gem-difluoroethyl substituted stilbene and diphenylethane derivatives, and a preparation method therefor and the use thereof. The present invention conducts a chemical structure modification with a gem-difluoroethyl at th...
|
|
WO/2019/023264A1 |
Aspects of the present disclosure include G6PD-modulating agents and methods for modulating a glucose-6-phosphate dehydrogenase (G6PD) in a sample using such agents. A G6PD-modulating agent can be dimeric and include two terminal carbocy...
|
|
WO/2019/018562A1 |
Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): ...
|
|
WO/2019/017336A1 |
This compound is represented by general formula (1). In general formula (1), R1 and R2 each independently denote a hydrogen atom, a methyl group or an ethyl group, and the sum of the number of carbon atoms in the group denoted by R1 and ...
|
|
WO/2019/014651A1 |
The present invention relates to cyclobenzaprine analogs and amitryptilene analogs, including deuterated forms useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
|
|
WO/2019/011711A1 |
The present invention relates to a to prepare ethylene amines of the formula NH2-(C2H4-NH-)pH wherein p is at least 2, or derivatives thereof wherein one or more units -NH-C2H4-NH- may be present as a cyclic ethylene urea unit (I) compri...
|
|
WO/2019/011708A1 |
The invention pertains to a process to prepare ethylene amines with n ethyleneunits and n+1 amine groups wherein n is at least 4, or urea derivatives of said ethylene amines, by reacting an ethanolamine-functional compound, an amine-func...
|
|
WO/2019/011710A1 |
The present invention relates to a process to prepare ethyleneamines of the formula NH2-(C2H4-NH-)PI-I wherein p is at least 3, or derivatives thereof wherein one or more units -NH-C2H4-NH- may be present as a cyclic ethylene urea unit o...
|
|
WO/2019/013709A1 |
Disclosed herein is a zero-dimensional hybrid organic-inorganic perovskite material of Formula (I) wherein A contains at least one aromatic or heteroaromatic ring, M is selected from Ge, Pb, Sn, Mn, Cu, Co, and Eu, and X is a halide or p...
|
|
WO/2019/010999A1 |
Provided are a quantum dot and a quantum dot preparation method. The method comprises the following steps: preparing a quantum dot solution, preparing an ion-containing organic ligand precursor, and adding the ion-containing organic liga...
|
|
WO/2019/012349A1 |
Embodiments of the present disclosure describe carbocyclic pseudo Tröger's base (CTB) amines. Embodiments of the present disclosure further describe microporous polymers derived from pseudo CTB amines, including, but not limited to, pol...
|
|
WO/2019/002190A1 |
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.
|
|
WO/2019/004587A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present disclosure, an organic electroluminesc...
|
|
WO/2018/237140A1 |
Inhibitors of human topoisomerase II (Top2) are the backbone of numerous cancer chemotherapy regimens. Unfortunately, the onset of toxicity severely limits the utility of these powerful drugs. There is some conservation between human Top...
|
|
WO/2018/234220A1 |
The present application relates to a polymer containing at least one structural unit of formula (I). The polymer is suitable for use in electronic devices.
|
|
WO/2018/232527A1 |
The present invention describes complex topical aqueous compositions for the effective delivery of active ingredients such as putrescine and Vitamin C into the skin. These compositions may be used in a variety of cosmetic and therapeutic...
|
|
WO/2018/233633A1 |
The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically...
|
|
WO/2018/230782A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. The compound according to the present invention is used for an organic layer, preferably a luminous layer, of an organic elec...
|
|
WO/2018/226376A1 |
Methods of making antidegradant compounds are disclosed in which a p-phenylenediamine is reacted with a diol to obtain mixtures comprising the antidegradant compounds.
|
|
WO/2018/226373A1 |
A compound represented bz the formula: (I) wherein each R is independently selected from the group consisting of (i) substituted or unsubstituted alkyl with C = 0 to 12 inclusive; wherein X1, X2, X3 and X4 are each independently selected...
|
|
WO/2018/225943A1 |
The present invention provides a novel compound for an organic light-emitting element, which can achieve efficiency improvement, low driving voltage, and/or enhanced longevity and can be used as a hole injection, hole transport, hole inj...
|
|
WO/2018/225991A1 |
Provided in the present invention are a compound capable of improving high luminous efficiency, low driving voltage, and a service life of a device; an organic electric device using the same; and an electronic device thereof.
|
|
WO/2018/226372A1 |
A method of making antidegradant compounds is disclosed, in which a p-phenylenediamine corresponding to formula IV is reacted with an alpha-hydroxy carbonyl compound corresponding to formula II to thereby obtain an enediamine, which is r...
|
|
WO/2018/225737A1 |
Provided is a catalyst for debenzylation reactions, which enables the achievement of a higher yield of a target product (a debenzylated product) in comparison to conventional Pd-supporting catalysts in a debenzylation reaction wherein a ...
|
|
WO/2018/226375A1 |
Methods of making antidegradant compounds of formula I are disclosed in which a p-phenylenediamine of formula IV is reacted with a diol of formula II to obtain mixtures comprising the antidegradant compounds.
|
|
WO/2018/224315A1 |
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst which contains one or more ...
|
|
WO/2018/226374A1 |
Antidegradant compounds are disclosed, and methods of making them, that are represented by the formula (I), wherein each X is independently selected from the group consisting of ethyl, methyl, or hydrogen. Also disclosed are diimine inte...
|
|
WO/2018/224316A1 |
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase, by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst containing Co, Ru and Sn.
|
|
WO/2018/224321A1 |
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase, by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst obtained by reducing a cat...
|
|
WO/2018/223347A1 |
Disclosed is a method for synthesizing an N-alkylaminophenyl alkyl ether, wherein the N-alkylaminophenyl alkyl ether is prepared by subjecting a nitrophenyl alkyl ether to hydrogenation reduction and alkylation, or wherein same may also ...
|
|
WO/2017/150859A9 |
The present specification provides a nitrogen-containing compound and an organic light emitting device comprising the same.
|
|
WO/2018/222384A1 |
Described herein is a fluorinated diaminoolefin of formula (I) (Rf 1CF2)(Rf 2)NCH2CH=CHCH2N(Rf 4)(CF2Rf 3) where: Rf 1 and Rf 3, are independently selected from F, a linear or branched perfluorinated alkyl group comprising 1-7 carbon ato...
|
|
WO/2018/221604A1 |
The present invention provides a method for industrially producing: a pyrimidine compound having pest control efficacy; 2-[4-(trifluoromethyl)phenyl]ethylamine, which is a production intermediate of the pyrimidine compound; a phenylethyl...
|
|
WO/2018/216903A1 |
The present invention provides a novel compound for an organic light-emitting device, and an organic light-emitting device using same, the novel compound enabling an increase in efficiency, a low driving voltage and/or an increase in lif...
|
|
WO/2018/211844A1 |
This compound is represented by general formula (1). In general formula (1), R1 and R2 are each independently an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an aryl group having 6 to 14 carbon atom...
|
|
WO/2018/213140A1 |
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...
|
|
WO/2018/212356A1 |
Stable perovskite films having substantially-no phase transition within a predetermined temperature range are disclosed. In the films, formation of carrier traps is suppressed. Thermally stable perovskite solar cells and light-emitting d...
|
|
WO/2018/206769A1 |
The present invention relates to indane derivatives of the formula (I) and mixtures thereof, wherein X is selected from groups of the formula -A-(NAr2), wherein A is a chemical bond or phenylene which is unsubstituted or substitutedby 1,...
|
|
WO/2018/208709A1 |
The present application discloses stilbene derivative compounds and compositions, and methods for treating ocular diseases, neurological disorders and protein aggregation-related disorders in patients using the compounds and compositions...
|
|
WO/2018/204532A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction betw...
|
|
WO/2018/203497A1 |
This diamine compound is represented by H2NH2C-Ro2-CH2NH2 (in the formula, Ro2 represents a resin acid dimer residue).
|
|
WO/2018/204424A1 |
The present invention provides for a method to produce a deep eutectic solvent (DES) comprising: (a) providing one or more lignin derived monomeric phenol, or a mixture thereof, in a solution, (b) introducing one or more hydrogen accepto...
|
|
WO/2018/198975A1 |
Provided is a light-emitting element having excellent luminance life. Disclosed is a light-emitting element comprising a positive electrode, a negative electrode, a first organic layer provided between the positive electrode and the nega...
|
|
WO/2018/196860A1 |
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...
|
|
WO/2018/195098A1 |
Disclosed are Type II Topoisomerase Inhibitors, analogs thereof, pharmaceutical compositions thereof, and methods of making and using these compounds and compositions. Methods of using the disclosed compounds to treat infections, such as...
|
|
WO/2018/192521A1 |
The present subject matter relates to compounds that have aggregation-induced emission (AIE) characteristics and are capable of generating Raman signals in the Ramancell-silent region (1800 cm -1-2800 cm -1). The compounds can be used in...
|
